(This is not a complete list of publications, but only a selection of the major ones.)


Volm, M., Wayss, K., Kaufmann, M. and Mattern, J.: Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Europ. J. Cancer 15, 983-993 (1978).


Cooperative Study Group for Sensitivity Testing of Tumors (KSST) (K. Goerttler, J. Mattern, M. Volm, K. Wayss, E. Weber et al.): In vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48, 2127-2135 (1981).


Volm, M., Brüggemann, A., Günther, M., Kleine, W., Pfleiderer, A. and Vogt-Schaden, M.: Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res. 45, 5180-5185 (1985).


Volm, M., Hahn, E.W., Mattern, J., Müller, Th., Vogt-Moykopf, I., and Weber, E.: Five-year follow up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 48, 2923-2928 (1988).


Volm, M., Efferth, Th., Bak, M., Ho, A.D., Mattern, J.: Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method. Eur. J. Cancer Clin. Oncol. 25, 743-749 (1989).


Pommerenke, E.W., Osswald, H., Hahn, E.W., and Volm, M.: Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Letters 55, 17-23 (1990).


Efferth, T. and Volm, M.: Antibody-directed therapy of multidrug-resistant tumour cells. Med. Oncol. Pharmacother. 9, 11-19 (1992).


Volm, M., Mattern, J., and Samsel, B.: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170 and glutathione S-transferase in human lung tumors. Cancer 70, 764-769 (1992).


Volm, M. and Mattern, J.: Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin-resistance and with patients' smoking habits. Carcinogenesis 13, 1947-1950 (1992).


Wodrich, W. and Volm M.: Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis 14, 1121-1124 (1993).


Koomägi, R., Mattern, J. and Volm, M.: Up-regulation of resistance-related proteins in human lung tumors with poor vascularization. Carcinogenesis 16, 2129-2133 (1995).


Pommerenke, E.W., Sinn, H. and Volm M.: Circumvention of doxorubicin-resistance in tumours by albumin conjugated-doxorubicin. Eur. J. Cancer 31A, 283-284 (1995).


Mattern, J., Kallinowski, F., Herfarth, Ch. and Volm, M.: Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int. J. Cancer 67, 20-23 (1996).


Stammler, G., Pommerenke, E.W., Masanek, U., Mattern, J. and Volm, M.: Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation. J. Exp. Ther. 1, 39-48 (1996).


Mattern, J., Koomägi, R. and Volm, M.: Xenotransplantability of human cancers in mice. J Natl Cancer Inst 90: 1747 (1998).


Volm, M., Rittgen, W. and Drings, P.: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77, 663-669 (1998).


Volm, M. and Rittgen, W.: Cellular predictive factors for drug response of lung cancer. Anticancer Res. 20, 3449-3458 (2000).


Volm, M., Koomagi, R., Mattern, J. and Efferth, T.: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Sr J Cancer 87, 251-257 (2002).


Volm, M. and Efferth, T.: Prediction of cancer drug resistance and implications for personalized medicine. Front. Oncol 5, 282 (2015).


Efferth, T., and Volm, M.: Multiple resistance to carcinogens and xenobiotics: P-glycoprotein as universal detoxifiers. Arch. Toxicol 91, 2515-2538 (2017).

to top
powered by webEdition CMS